ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Phathom Pharmaceuticals

< Previous 1 2 3 Next >

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

December 14, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers HTGC PHAT

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

December 06, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

November 28, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

November 09, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

November 01, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

October 30, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

October 25, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

September 26, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

September 05, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

August 21, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

August 10, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD

June 12, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

June 09, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

June 01, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

May 23, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

May 23, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

May 23, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Reports First Quarter 2023 Results

May 10, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

May 09, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

April 12, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch

April 04, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 28, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Provides Regulatory Updates

February 09, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

January 08, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

January 03, 2023

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 08, 2022

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences

November 03, 2022

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

November 01, 2022

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers HTGC PHAT

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)

October 24, 2022

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

October 23, 2022

From Phathom Pharmaceuticals

Via GlobeNewswire

Tickers PHAT

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.